Table 2.
Formulations | Z-Aved (nm) | PdIe | ZPf (mV) | EEg (%) | LCh(¼g/mg) (%) | ||||
---|---|---|---|---|---|---|---|---|---|
Antigens | CpG | MPLAi | Antigens | CpG | MPLAi | ||||
NP[Ma] | 134 ± 6.1 | 0.067 ± 0.024 | −6.30 ± 0.80 | 57.8 ± 7.12 | 64.67 ± 3.67 | 99.97 | 14.42 ± 3.43 | 2.33 ± 0.13 | 3.00 |
NP[M+Gb] | 138 ± 4.7 | 0.072 ± 0.021 | −4.57 ± 0.65 | 53.1 ± 10.08 | 83.49 ± 0.41 | 99.96 | 26.56 ± 5.04 | 5.43 ± 0.03 | 4.80 |
NP[M+G+GalCerc] | 138 ± 6.1 | 0.159 ± 0.038 | −4.17 ± 1.20 | 51.98 ± 0.78 | 78.71 ± 4.90 | 99.94 | 25.99 ± 0.39 | 5.12 ± 0.32 | 4.80 |
Melan-A (26–35(27L), sequence ELAGIGILTV).
gp100 (44–59), sequence WNRQLYPEWTEAQRLD.
α-Galactosylceramide.
Hydrodynamic mean diameter (Z-ave).
Polydispersity index (PdI).
Zeta potential (ZP).
Entrapment efficiency (EE).
Loading capacity (LC).
MPLA content determined by LAL Chromogenic Endotoxin Quantitation Kit® (SD is zero due to high loading values and kit sensitivity).